An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
Enregistré dans:
Auteurs principaux: | Alison Findlay, Craig Turner, Heidi Schilter, Mandar Deodhar, Wenbin Zhou, Lara Perryman, Jonathan Foot, Amna Zahoor, Yimin Yao, Ross Hamilton, Mary Brock, Christina Raso, Jessica Stolp, Marie Galati, Dieter Hamprecht, Brett Charlton, Wolfgang Jarolimek |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c99b1b5618214a2193bedd33dab46b7d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Facilitation of molecular motion to develop turn-on photoacoustic bioprobe for detecting nitric oxide in encephalitis
par: Ji Qi, et autres
Publié: (2021) -
LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling
par: Caixia Zhang, et autres
Publié: (2021) -
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment
par: Jin Yang, et autres
Publié: (2016) -
Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis Partly by Inhibiting the Expression of LOX and LOXL-2
par: Xiang Tong, et autres
Publié: (2021) -
The lncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2
par: Philipp Neumann, et autres
Publié: (2018)